We are seeing patients in-person and through Video Visits. Learn more about how we’re keeping you safe and please review our updated visitor policy. Please also consider supporting Weill Cornell Medicine’s efforts to support our front-line workers.
Sandra and Edward Meyer Cancer Center

Warning message

The subscription service is currently unavailable. Please try again later.

You are here


Emergence of CAR T-cell therapy in hematologic cancers

Friday, May 5, 2017

John P. Leonard, M.D., associate dean of Clinical Research, interim chair of the Department of Medicine, talks to OncLive about the emergence and potential of chimeric antigen receptor (CAR) T-cell therapy across hematologic malignancies. Much of the encouragement with CAR T-cell therapy has been observed in acute lymphoblastic leukemia, Leonard explains. There are a lot of data approaching in some of the hard-to-treat lymphomas, particularly resistant diffuse large B-cell lymphoma. Additionally, there are patients who have had excellent responses that seem to be durable. However, the biggest challenge currently with this treatment is patient selection, he says. There are patients who will not be candidates for CAR T-cell therapy because of age, comorbidities, and aggressive disease. Ultimately, it will come down to how many patients benefit and how durable will the responses be.